Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, parallel-group, phase II randomized study in patients with
oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone.
Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by
Lu-PSMA (arm A) or Stereotactic Radiotherapy (arm B)
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori